Financial Performance - The net loss attributable to Class A Ordinary Shareholders for the three months ended September 30, 2024, was $22,942,000, compared to a loss of $8,270,000 for the same period in 2023, representing an increase in loss of approximately 177.5%[15]. - For the three months ended September 30, 2023, the net loss was $20.702 million, compared to a net loss of $8.270 million for the same period in the previous year[18]. - As of September 30, 2024, total shareholders' equity was $154.587 million, with an accumulated deficit of $142.272 million[19]. - As of September 30, 2024, the company reported a net loss of $20.7 million for the three months and $38.8 million for the nine months, with an accumulated deficit of $142.3 million[122]. Assets and Liabilities - As of September 30, 2024, the company reported total current assets of $188,975,000, a significant increase from $100,843,000 as of December 31, 2023, representing an increase of approximately 87%[11]. - The company reported a total liability of $18,244,000 as of September 30, 2024, down from $21,292,000 as of December 31, 2023, indicating a decrease of about 14.4%[12]. - The company’s total shareholders' equity increased to $154,587,000 as of September 30, 2024, from $60,871,000 as of December 31, 2023, representing an increase of approximately 154.0%[13]. - The total assets of the company as of September 30, 2024, were $189,071,000, up from $100,843,000 as of December 31, 2023, reflecting an increase of approximately 87.2%[11]. Cash Flow and Financing - The company had cash and cash equivalents of $188.221 million as of September 30, 2023, up from $103.859 million at the beginning of the period[28]. - Cash provided by financing activities for the nine months ended September 30, 2024 was $110.7 million, consisting of $62.5 million from Class A Ordinary Shares issuance and $50.0 million from Pre-Funded Warrants[180]. - The company raised a total of $10.0 million from the sale of convertible preferred stock, $7.6 million from a promissory note, $56.7 million from a business combination, and $80.0 million from an April 2023 private placement[121]. - The company completed an April 2024 Private Placement, issuing 18,732,301 Class A Ordinary Shares at $3.108 per share, raising approximately $108.3 million[79]. Operating Expenses - Total operating expenses for the three months ended September 30, 2024, were $19,319,000, compared to $10,187,000 for the same period in 2023, reflecting an increase of approximately 90.0%[15]. - General and administrative expenses rose by $7.1 million to $13.3 million for the three months ended September 30, 2024, reflecting a 114% increase year-over-year[154]. - Research and development expenses for the nine months ended September 30, 2024, were $15,161,000, compared to $37,079,000 for the same period in 2023, showing a decrease of approximately 59.1%[15]. - Research and development expenses increased by $2.1 million to $6.0 million for the three months ended September 30, 2024, representing a 52% increase compared to the same period in 2023[153]. Shareholder Equity and Shares - The company issued 20,090,128 Class A Ordinary Shares in connection with an April 2024 private placement, raising $55.221 million after $7.2 million in transaction costs[19]. - The company had 65,293,530 Class A Ordinary Shares outstanding as of September 30, 2024[19]. - The total number of shares issuable upon exercise of options to purchase Class A Ordinary Shares increased from 5,681,471 as of September 30, 2023, to 9,318,906 as of September 30, 2024[47]. - The company authorized 300,000,000 Class A Ordinary Shares and 1,000,000 preferred shares as of March 16, 2023[74]. Future Obligations and Risks - The company is obligated to make future milestone payments to Lilly totaling up to $155 million and sales milestone payments up to $440 million under the 2022 and 2023 Lilly Licenses[70]. - The company has not yet conducted any clinical trials and has no product candidates approved for sale, with no revenue generated from product sales[121]. - The company may need to rely on additional financing to achieve its business objectives, as adequate financing may not be available on acceptable terms[176]. - The company has not included future milestone or royalty payments in its financial obligations due to their uncertain timing and amounts[189]. Management and Corporate Structure - A CEO transition was approved, with Robert Lisicki set to take over from founder Someit Sidhu effective April 8, 2024[143]. - The Company completed a business combination on March 20, 2023, resulting in the establishment of Zura Bio Limited as the new holding company[30]. - The business combination has been accounted for as a reverse recapitalization, with Legacy Zura as the accounting acquirer[31]. Regulatory and Compliance - The Company’s future product candidates require FDA approvals, and there is no assurance that any will receive necessary approvals[39]. - The Company’s financial statements are prepared in accordance with U.S. GAAP and may not be comparable to those of other public companies due to its emerging growth status[34]. - The company qualifies as a "smaller reporting company" under the Securities Act and Exchange Act, with a market value of Class A Ordinary Shares held by non-affiliates being less than $250 million[196].

Financial Performance - Cash and cash equivalents totaled $188.2 million as of September 30, 2024, up from $99.8 million as of December 31, 2023, indicating a significant increase of 88.4%[7] - The net loss for Q3 2024 was $22.9 million, or $0.26 per share, compared to a net loss of $8.3 million, or $0.18 per share, for the same period in 2023[10] - The accumulated deficit increased to $142.3 million as of September 30, 2024, from $103.5 million as of December 31, 2023[17] Expenses - Research and development expenses for Q3 2024 were $6.0 million, an increase of 50% compared to $4.0 million for the same period in 2023[8] - General and administrative expenses rose to $13.3 million in Q3 2024, up 114.5% from $6.2 million in Q3 2023, primarily due to a one-time non-cash expense of $5.3 million in share-based compensation[9] Clinical Trials - The Phase 2 clinical trial for tibulizumab in systemic sclerosis is expected to initiate in Q4 2024, with the protocol finalized in September 2024[3] - A third-party CRO has been selected to oversee the Phase 2 clinical program for tibulizumab in hidradenitis suppurativa, with trial initiation anticipated in Q2 2025[3] Capital Structure - The company completed a warrant exchange program in August 2024, simplifying its capital structure[6] - An "at-the-market" (ATM) program is in place as of September 2024, providing increased financial flexibility for the company[6] Assets - The total assets as of September 30, 2024, were $189.1 million, compared to $100.8 million as of December 31, 2023[15]

Financial Performance - The company reported a net loss of $10.3 million for the three months ended June 30, 2024, and $18.1 million for the six months ended June 30, 2024, with an accumulated deficit of $121.6 million as of June 30, 2024[107]. - The net loss attributable to ordinary shareholders was $13.4 million for the six months ended June 30, 2024, a decrease of $41.3 million (76%) compared to the same period in 2023[144]. - The company incurred a net loss before redeemable noncontrolling interest of $18.1 million for the six months ended June 30, 2024, compared to a net loss of $43.8 million for the same period in 2023[164][165]. - The net loss attributable to Ordinary Shareholders of the Company was $12.7 million for the three months ended June 30, 2024, a decrease of $21.4 million (48%) compared to the prior year[134]. Revenue and Sales - The company has not generated any revenue from product sales and has a limited operating history focused on business planning and raising capital[106]. - The company has not generated any revenue since inception and does not expect to do so for at least the next few years[157]. Capital and Financing - The company raised a total of $112.5 million in gross proceeds from the April 2024 Private Placement, issuing 18,732,301 Class A Ordinary Shares and pre-funded warrants[111]. - The company generated approximately $56.7 million in net proceeds from the Business Combination completed on March 20, 2023[110]. - As of June 30, 2024, the company had cash and cash equivalents of $188.4 million, funded through various financing activities including a $112.5 million private placement[155]. - Net cash provided by financing activities for the six months ended June 30, 2024, was $105.3 million, a decrease of 15.9% from $125.4 million in the same period of 2023[166][167]. Expenses - Research and development expenses decreased by $22.7 million (80%) to $5.5 million for the three months ended June 30, 2024, primarily due to a $27.2 million expense related to an IPR&D license acquisition in the prior year[134][136]. - General and administrative expenses increased by $0.5 million (10%) to $6.2 million for the three months ended June 30, 2024, driven by higher compensation and professional fees[137]. - The Company anticipates a substantial increase in research and development expenses as it continues to develop product candidates and manufacturing processes[131]. - General and administrative expenses increased by $2.5 million (29%) for the six months ended June 30, 2024, mainly due to a $2.0 million increase in compensation-related expenses[148]. - Total operating expenses decreased by $21.5 million (52%) for the six months ended June 30, 2024, compared to the same period in 2023[144]. Future Outlook - The company plans to raise substantial additional capital in the future to support ongoing clinical development and operational needs[131]. - Future operations are dependent on the ability to finance cash requirements for ongoing research and development activities[156]. - The company anticipates ongoing increases in expenses related to research and development and administrative costs as it seeks marketing approval for product candidates[158]. Agreements and Obligations - The company is obligated to make development milestone payments to Lilly of up to $155.0 million and sales milestone payments of up to $440 million based on net sales thresholds for products developed from ZB-106[117]. - The company entered into a license agreement with Lilly for the exclusive rights to develop, manufacture, and commercialize a bispecific antibody, ZB-106, with an initial payment of $5.0 million made during the six months ended June 30, 2024[114]. - The company entered into a Lonza License agreement, which includes potential annual payments of up to middle six-figure amounts per sublicense and royalties of up to low-single digit percentages of net sales[169]. - A master services agreement with WuXi Biologics was established in July 2023, obligating the company to pay service fees as specified in each work order[170]. Operational Changes - The company has incurred significant operating losses since inception and anticipates expenses will increase significantly as it advances preclinical and clinical development of product candidates[107]. - The company has a new CEO, Robert Lisicki, effective April 8, 2024, following a transition from founder Someit Sidhu[123]. - The Company commenced an exchange offer for outstanding IPO warrants, offering 0.30 Class A ordinary shares for each warrant tendered[124]. - The Exchange Offer and Consent Solicitation resulted in 6,703,428 public warrants (approximately 97.2%) and 4,080,580 private placement warrants (approximately 69.0%) being validly tendered[125]. - The Company issued 3,235,184 Class A ordinary shares in exchange for 10,784,008 IPO warrants, with a mandatory exchange ratio of 0.27 Class A ordinary shares for each remaining IPO warrant[126]. Economic Impact - Macroeconomic conditions, including geopolitical conflicts and inflation, continue to impact the Company's business and may materially affect future results[127]. - Cash used in operating activities for the six months ended June 30, 2024, was $11.6 million, compared to $8.4 million for the same period in 2023, reflecting an increase of 38.1%[164][165]. - Cash used in investing activities for the six months ended June 30, 2024, was $5.0 million, slightly lower than $5.8 million in the same period of 2023[166]. Non-Cash Charges - Non-cash charges for the six months ended June 30, 2024, included $6.7 million, primarily from share-based compensation of $5.3 million[164]. Company Classification - The company remains classified as an "emerging growth company" and a "smaller reporting company," allowing it to take advantage of reduced disclosure requirements[177][179].

Financial Performance - Net loss for Q2 2024 was $12.7 million, or $0.17 per share, compared to a net loss of $44.9 million, or $1.31 per share, in Q2 2023[5] - Net loss attributable to Class A Ordinary Shareholders of Zura was $12,666,000, a reduction of 71.8% from $44,900,000 in 2023[13] - Net loss per share attributable to Class A Ordinary Shareholders was $0.17, significantly improved from $1.31 in the prior year[13] - Loss from operations for June 2024 was $11,759,000, compared to $33,905,000 in 2023[13] - The company reported a loss before income taxes of $(10,329,000), down from $(34,025,000) in 2023[13] Cash and Investments - Zura Bio reported cash, cash equivalents, and investments of $188.4 million as of June 30, 2024, up from $99.8 million as of December 31, 2023[3] - The company raised approximately $112.5 million in gross proceeds from a private placement in April 2024, expected to support operations through 2027[3] - Zura Bio's total assets increased to $189.5 million as of June 30, 2024, compared to $100.8 million as of December 31, 2023[12] Research and Development - Research and Development (R&D) expenses decreased to $5.5 million in Q2 2024, down from $28.2 million in the same period in 2023, primarily due to a $27.2 million expense related to the acquisition of tibulizumab in Q2 2023[4] - Research and development expenses amounted to $5,539,000, down from $28,230,000 in the previous year[13] - The company anticipates utilizing external data readouts to inform the initial indication selection for crebankitug by the end of 2024[7] - Zura Bio expects to initiate Phase 2 studies for tibulizumab in systemic sclerosis (SSc) in Q4 2024 and in hidradenitis suppurativa (HS) in Q2 2025[1] Operating Expenses - General and Administrative (G&A) expenses increased to $6.2 million in Q2 2024, compared to $5.7 million in Q2 2023[5] - Total operating expenses for June 2024 were $11,759,000, a decrease of 65.3% compared to $33,905,000 in 2023[13] - Total other income/expense, net was $(1,430,000), compared to $120,000 in the previous year[13] - Interest income for the period was $(2,196,000), with no interest income reported in the prior year[13] Corporate Developments - Zura Bio established a Scientific Advisory Board in June 2024, comprising leading experts in rheumatology, dermatology, and immunology[2] - The company completed a warrant exchange program in August 2024 to simplify its capital structure[2]

Financial Performance - Cash and cash equivalents decreased to $89.8 million as of March 31, 2024, from $99.8 million as of December 31, 2023[4]. - Net loss for Q1 2024 was $7.7 million, an improvement from a net loss of $9.6 million in the same period of 2023[9]. - Total operating expenses for Q1 2024 were $8.4 million, compared to $7.7 million in Q1 2023[20]. Funding and Cash Runway - Zura Bio raised approximately $112.5 million in an oversubscribed private placement, providing a cash runway through 2027[3]. - The projected cash runway supports operations through 2027, factoring in the recent private placement[5]. Research and Development - Research and Development (R&D) expenses for Q1 2024 were $3.6 million, a decrease of $1.3 million compared to $4.9 million in Q1 2023[7]. - The company is on track to initiate Phase 2 studies for tibulizumab in systemic sclerosis (SSc) in Q4 2024 and hidradenitis suppurativa (HS) in Q2 2025[5]. - Zura Bio is developing three assets that are Phase 2 ready, targeting autoimmune and inflammatory diseases[13]. Administrative Expenses and Leadership - General and Administrative (G&A) expenses increased to $4.8 million in Q1 2024, up from $2.8 million in Q1 2023, primarily due to increased personnel costs[8]. - The company appointed Robert Lisicki as CEO and Kiran Nistala as CMO, enhancing its leadership team[6].

Financial Performance - As of March 31, 2024, Zura Bio Limited reported a net loss of $7.7 million and an accumulated deficit of $111.2 million[116]. - The net loss attributable to ordinary shareholders was $730,000 for the three months ended March 31, 2024, a significant decrease of 93% from the net loss of $9.8 million in the same period of 2023[150]. - The company expects to continue incurring significant operating losses and may never become profitable, with no revenue generated since inception[160]. - Cash used in operating activities for Q1 2024 was $4.98 million, compared to $3.26 million in Q1 2023, reflecting an increase in operational costs[169][171]. Funding and Capital Structure - The company raised a total of $112.5 million in gross proceeds from a Private Placement in April 2024, selling Class A Ordinary Shares and Pre-Funded Warrants[122]. - The company completed a Business Combination on March 20, 2023, generating approximately $56.7 million in net proceeds[119]. - The company reported a net cash increase of $42.4 million from financing activities in Q1 2023, primarily from the Business Combination[174]. - The company expects net proceeds from the Business Combination and private placements to fund operating expenses and capital requirements for at least the next twelve months[166]. Research and Development - Zura Bio Limited has not generated any revenue from product sales and has not conducted any clinical tests since its inception[115]. - Zura Bio Limited's lead product candidates are in the clinical testing stage, with plans to advance preclinical and clinical development significantly[116]. - The company is obligated to make development milestone payments to Lilly up to an aggregate of $155.0 million and sales milestone payments up to $440 million based on net sales thresholds[130]. - Future expenses are anticipated to increase due to ongoing research and development activities and administrative costs associated with being a public company[162]. Expenses and Cost Management - General and administrative expenses increased by $2.0 million to $4.8 million for the three months ended March 31, 2024, representing a 69% increase year-over-year[152]. - Research and development expenses decreased by $1.3 million to $3.6 million for the three months ended March 31, 2024, a 26% decline compared to the same period in 2023[151]. - Total operating expenses rose by $660,000 to $8.4 million for the three months ended March 31, 2024, a 9% increase compared to the previous year[150]. - The company anticipates significant increases in expenses related to scaling up clinical and regulatory capabilities and establishing commercialization infrastructure[116]. Corporate Governance and Compliance - A CEO transition occurred on April 8, 2024, with Robert Lisicki taking over from Someit Sidhu[139]. - The company remains an emerging growth company and may elect to extend the transition period for complying with new accounting standards[188]. - The company qualifies as a "smaller reporting company" under the Securities Act and Exchange Act, with a market value of Class A Ordinary Shares held by non-affiliates below $250 million or annual revenue under $100 million[190]. - The company is exempt from compliance with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act[190]. Licensing and Agreements - The company entered into a license agreement with Lilly for the development of a bispecific antibody, making an initial payment of $5.0 million[124]. - The company has entered into a Cell Line License Agreement with WuXi Biologics, involving a non-refundable license fee of $150,000 and potential royalty payments based on global net sales[181]. - The company is obligated to make multimillion dollar milestone payments to Pfizer and Lilly upon achieving certain development, regulatory, and sales milestones[163]. - Ongoing royalties to Pfizer and Lilly are expected to be in the mid-single digits to low double-digits percentage range based on net sales thresholds[165].

Financial Performance - Zura Bio Limited has incurred significant operating losses, with a net loss of $60.4 million for the year ended December 31, 2023, compared to a net loss of $25.7 million for the year ended December 31, 2022[465]. - The company reported a total operating expense of $62.6 million for the year ended December 31, 2023, an increase of 131% compared to $27.2 million for the period from January 18, 2022, to December 31, 2022[504]. - The company incurred a net loss of $60.4 million for the year ended December 31, 2023, representing a 135% increase from a net loss of $25.7 million in 2022[504]. - Research and development expenses rose to $44.0 million in 2023, up 86% from $23.7 million in 2022, primarily due to increased costs associated with acquiring licenses and manufacturing product candidates[504][505]. - General and administrative expenses increased by 437% to $18.6 million in 2023, compared to $3.5 million in 2022, driven by higher compensation and professional fees[504][506]. - The company has not generated any revenue from product sales and has not conducted any clinical tests since its inception[464]. - The company has not generated any revenue since inception and does not expect to do so for at least the next few years[518]. Funding and Capital Structure - The company has raised a total of $10.0 million from the sale of convertible preferred stock, $7.6 million from a promissory note, $56.7 million from a Business Combination, and $80.0 million from an April 2023 Private Placement[464]. - The April 2023 Private Placement involved the issuance of 15,041,530 Class A Ordinary Shares at $4.25 per share, raising an aggregate of $80.0 million[475]. - Cash provided by financing activities for the year ended December 31, 2023 was $121.3 million, including $56.7 million from the Business Combination and $59.7 million from the April 2023 Private Placement[530]. - As of December 31, 2023, the company had cash and cash equivalents of $99.8 million[516]. - The company anticipates needing substantial additional funding for ongoing operations and research and development activities[522]. Research and Development - The company is focused on advancing the preclinical and clinical development of its product candidates, including the ZB Assets, and seeks regulatory approval for successful candidates[465]. - The company plans to significantly increase its research and development expenses in the foreseeable future to support the development of product candidates and manufacturing processes[500]. - The company recognized $27.2 million in expenses related to the acquisition of an in-process research and development license from Lilly during the year ended December 31, 2023[505]. - External costs related to process development and clinical activities are recognized based on progress evaluations and service provider information[543]. Agreements and Obligations - Zura Bio entered into a license agreement with Lilly for the development of a bispecific antibody (ZB-106), involving an upfront payment of $5.8 million and 1,000,000 Class A Ordinary Shares valued at $7.84 per share[477]. - The company is obligated to make up to $155.0 million in development milestone payments and up to $440 million in sales milestone payments based on net sales of products developed from ZB-106[481]. - The company is obligated to make milestone payments to Lilly totaling up to $155.0 million and sales milestone payments up to $440.0 million based on net sales thresholds of products developed from licensed compounds[485]. - The company has a potential multi-million dollar transaction payment obligation if there are changes in control or if it sublicenses or divests its rights to products[488]. - The company has not included future milestone or royalty payments in its financial statements due to uncertainty regarding timing and amounts[539]. Operational Plans - The company plans to scale up its clinical and regulatory capabilities, hire additional personnel, and establish a commercialization infrastructure to support future product candidates[465]. - The company expects to incur significant commercialization expenses related to sales, marketing, manufacturing, and distribution if product candidates receive approval[519]. Shareholder and Stock Information - Zura Bio's Class A Ordinary Shares began trading on Nasdaq under the symbols "ZURA" and "ZURAW" following the Business Combination on March 21, 2023[472]. - The company issued 4,900,222 shares of Series Seed Preferred Shares to Stone Peach Properties as part of an acquisition arrangement, with options for both parties to buy or sell shares at specified prices[484]. - The deemed dividend to redeemable noncontrolling interest was $10.9 million for the year ended December 31, 2023, due to modifications of terms of the Z33 Series Seed Preferred Shares[514]. - The company has not paid dividends on its ordinary shares and has no plans to do so, using an expected dividend yield of zero in its financial assessments[549]. Emerging Growth Company Status - The company remains classified as an emerging growth company, allowing it to delay the adoption of certain accounting standards until they apply to private companies[554]. - The company qualifies as a smaller reporting company, which allows it to present only two years of audited financial statements and have reduced disclosure obligations[559].

Financial Position - Zura Bio reported a cash position of $99.8 million as of December 31, 2023, compared to $1.6 million as of December 31, 2022, indicating a significant increase in liquidity[10]. - Zura Bio's total assets increased to $100.8 million as of December 31, 2023, from $5.3 million in 2022, reflecting substantial growth in the company's financial position[19]. Expenses - Research and Development (R&D) expenses for 2023 were $44.0 million, an increase of 85.5% from $23.7 million in 2022, primarily due to higher manufacturing and licensing costs[11]. - General and Administrative (G&A) expenses rose to $18.6 million in 2023, up from $3.5 million in 2022, reflecting a 531.4% increase mainly due to personnel compensation and professional services[12]. - Total operating expenses for the year ended December 31, 2023, were $62,638,000, a significant increase from $27,162,000 in 2022, representing a growth of 130%[21]. - Research and development expenses rose to $43,999,000 in 2023, compared to $23,689,000 in 2022, indicating an increase of 85%[21]. Net Loss - The net loss for the year ended December 31, 2023, was $60.4 million, compared to a net loss of $25.7 million for the previous year, representing an increase of 134.5%[13]. - The net loss attributable to Class A Ordinary Shareholders of Zura for 2023 was $69,243,000, up from $32,390,000 in 2022, reflecting a 114% increase in losses[21]. - The net loss per share attributable to Class A Ordinary Shareholders of Zura was $2.09 for 2023, compared to $141.97 in 2022[21]. - Loss from operations for the year ended December 31, 2023, was $62,638,000, compared to $27,162,000 in 2022, marking an increase of 130%[21]. - The loss before income taxes for 2023 was $60,563,000, compared to $27,333,000 in 2022, indicating an increase of 121%[21]. Corporate Developments - Zura Bio plans to initiate a Phase 2 clinical trial for tibulizumab in systemic sclerosis in the second half of 2024[6]. - The company raised approximately $145 million in the first half of 2023 to support its pipeline and operations, including $80 million from institutional biotech investors[9]. - Zura Bio joined the Russell 2000® and Russell 3000® Indexes in June 2023, enhancing its market visibility[9]. - The company is advancing ZB-168 and torudokimab towards Phase 2 readiness while monitoring external catalysts in 2024[3]. - The company appointed Robert Lisicki as CEO, effective April 8, 2024, to lead the organization through its next phase of development[4]. Other Financial Metrics - Total other expense/(income), net for 2023 was $(2,075,000), a decrease from $171,000 in 2022[21]. - The change in fair value of private placement warrants resulted in a loss of $724,000 in 2023, with no comparable figure in 2022[21]. - The deemed dividend to redeemable noncontrolling interest was $(10,875,000) in 2023, with no comparable figure in 2022[21]. - The weighted-average Class A Ordinary Shares used in computing net loss per share increased to 33,064,036 in 2023 from 228,148 in 2022[21].

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40598 ZURA BIO LIMITED (Exact name of Registrant as specified in its Charter) Cayman Islands 98-1725736 (S ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40598 ZURA BIO LIMITED (Exact name of Registrant as specified in its Charter) Cayman Islands 98-1725736 (State ...